The FDA approved Bosaya and Aukelso, biosimilars of Prolia and Xgeva, respectively, for the treatment of solid tumors, like ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (FDA) ...

USFDA approved affordable biosimilars Bosaya and Aukelso approved by Biocon Biologics Ltd, offering treatment options for ...

The Food and Drug Administration (FDA) has approved Bosaya ™ (denosumab-kyqq) and Aukelso ™ (denosumab-kyqq), biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively.

Shares of the company ended 1.6% lower at a price of ₹354.40 on the BSE. Last week's losses have dragged the stock 4% lower ...

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) and XBRYK™ (denosumab-dssb; 120 mg vial), referencing ...

Celltrion today announced that Health Canada has approved Stoboclo® and Osenvelt® (CT-P41), biosimilars referencing Prolia® ...

Biocon rose 2.20% to Rs 362.20 after the company's subsidiary, Biocon Biologics, received approval from the US Food and Drug Administration (USFDA) for Bosaya and Aukelso, biosimilars of Amgen's ...

Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgen’s bone cancer drug XGEVA, used to prevent fractures in those with bone metastases from solid tumors ...

Fresenius announced today that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) - in the United States. This press ...

Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced Wednesday that the U.S.

Biocon Biologics gets US FDA nod for Bosaya & Aukelso to treat osteoporosis and bone loss: Our Bureau, Bengaluru Thursday, September 18, 2025, 13:45 Hrs [IST] Biocon Biologics, a ...